A convolution-based in vitro-in vivo correlation model for methylphenidate hydrochloride delayed-release and...

Area of Science:

• Pharmacokinetics
• Drug Delivery Systems
• Pharmaceutical Sciences

Background:

• Attention deficit hyperactivity disorder (ADHD) is commonly treated with methylphenidate hydrochloride.
• JORNAY PM® is a novel delayed-release and extended-release capsule formulation of methylphenidate hydrochloride.
• Post-approval manufacturing changes require robust methods to ensure consistent drug performance.

Purpose of the Study:

• To develop a Level A in vitro-in vivo correlation (IVIVC) model for extended-release methylphenidate hydrochloride.
• To establish a point-to-point correlation between in vitro drug dissolution and in vivo drug absorption.
• To support post-approval manufacturing changes for JORNAY PM®.

Main Methods:

• Utilized dissolution data from three in vitro release formulations (fast, medium, slow).
• Employed pharmacokinetic data from two in vivo studies.
• Developed the IVIVC model using a convolution-based approach, incorporating the unit impulse response function and convolution integral.
• Analyzed temporal differences using scatterplots and Levy plots.

Main Results:

• A Level A IVIVC model was successfully developed for extended-release methylphenidate hydrochloride.
• The model demonstrated internal predictability, validating its predictive capability.
• The IVIVC model effectively links in vitro dissolution profiles to in vivo absorption characteristics.

Conclusions:

• The developed IVIVC model provides a valuable tool for predicting in vivo drug performance based on in vitro dissolution data.
• This model can facilitate regulatory submissions and support manufacturing process adjustments for extended-release methylphenidate hydrochloride.
• The IVIVC approach enhances the understanding and control of drug product quality and therapeutic equivalence.